Harvard Pilgrim has developed a clinical medical policy on the treatment of uterine fibroids. This policy takes effect on November 1, 2015, and was developed to provide greater clarity on the medical necessity of certain treatments.
Harvard Pilgrim covers the treatment of uterine fibroids when it is medically necessary. After a review of the research, Harvard Pilgrim has determined that clinical literature supports not treating asymptomatic fibroids. For symptomatic fibroids, the following treatments are considered medically necessary:
- Transcatheter uterine artery embolization (UAE)
Harvard Pilgrim considers the following treatments for uterine fibroids experimental and investigational and does not provide coverage for them:
- Laser ablation
- Image-guided thermal ablation using ultrasonography or magnetic resonance imaging (MRI) or MR-guided focused US (e.g. ExAblate, Acessa System)
For further information, please refer to the Uterine Fibroid Treatments Medical Policy posted on our provider website.